Our Blueprint
Read posts
Colors of SM program launches to illuminate the profound and poorly understood impacts of living with systemic mastocytosis through the transformative power of creative arts
July 12, 2024
Systemic mastocytosis (SM) can significantly affect all aspects of people’s lives, and creating a shared understanding of these real-world impacts is crucial to support and…
Read moreUnderstanding mast cells as a powerful target for treating allergic and inflammatory diseases
May 16, 2024
Blueprint Medicines was founded on the belief that the research and development of innovative medicines could be accelerated. To bring this idea to life, we…
Read moreA day in the life of a Medical Science Liaison: Collaborating with physicians to advance patient care
April 11, 2024
An interview with Amy Monpara and Rahul Kalathiya, Senior Medical Science Liaisons Across our organization, teams work together in pursuit of a common goal to…
Read moreOur dedication to understanding SM: Connecting the dots with the PROSPECTOR Study
March 27, 2024
Mast cell activation syndromes (MCAS) are a group of disorders characterized by the accumulation and/or increased activation of mast cells and release of various mediators…
Read moreHonoring Rare Disease Day: An annual movement supported by a daily commitment to improving patients’ lives
February 29, 2024
Since our company’s inception in 2011, we’ve worked to bring innovative medicines to patients in need of new treatment options, including those living with a…
Read moreFinding patterns in symptom data to help improve patient care: Building the SM profile with outcomes research and real-world evidence
January 15, 2024
Every disease has a story, including its natural history, clinical presentation, signs and symptoms, and effect on a person’s quality of life. While these factors…
Read more“When the hoofbeats are zebras”: Using AI to improve SM diagnosis times
December 15, 2023
There is an old adage in medicine: “When you hear hoofbeats, think horses, not zebras.” In other words, think of common illnesses when evaluating patients…
Read moreAn enduring work of art that conveys…
December 11, 2023
Sharing dinner every night with family. Adapting to a new culture. Recovering from the unimaginable with the help of your dog. So often, it is…
Read moreWomen’s leadership award puts the spotlight on Blueprint’s intentional approach to business and culture
November 2, 2023
The Women’s Edge, a non-profit dedicated to advancing women in leadership, and the Boston Globe Magazine have named Blueprint Medicines one of the Top 100…
Read moreIt’s SMthing: Using patient insights and online search patterns to connect more people to information about systemic mastocytosis
August 16, 2023
We knew that a pattern existed, but no one was seeing it. Occurring in about 32,000 people in the United States, systemic mastocytosis is a…
Read moreThis is Our Blueprint
June 5, 2023
Precision medicine is a term that is used a lot in the biotech industry. Precision medicine hopes to deliver dramatically better and safer treatments by…
Read moreRecognition of Blueprint Medicines’ Intentional
Work to Diversify Our Leadership
May 8, 2023
Years of intentional work to diversify Blueprint Medicines’ leadership is being recognized. A report from the Eos Foundation found Blueprint Medicines was one of the…
Read moreThe importance of Rare Disease Day
February 28, 2023
Rare Disease Day is a very important reminder of the struggles faced by those living with rare conditions across the world, including their family and…
Read moreInternational Mastocytosis and Mast Cell Diseases Awareness Day 2022
October 17, 2022
Since early in our company’s history, we’ve been deeply committed to advancing care for systemic mastocytosis as we aim to address unmet patient needs. This…
Read moreAACR Annual Meeting 2022: Showcasing our Precision Therapy Pipeline
April 8, 2022
At the American Association for Cancer Research (AACR) Annual Meeting 2022, we’re presenting new clinical and preclinical data for multiple programs across our precision therapy…
Read moreImplementing a meaningful and sustainable equity, diversity and inclusion strategy
January 18, 2022
Originally published on MassBio.org December 20, 2021 At Blueprint Medicines, we’ve been committed to equity, diversity, and inclusion (ED&I) since our company’s founding in 2011.…
Read moreThe right moment for thoughtful transition of leadership at Blueprint Medicines
January 12, 2022
Last week, we announced that Jeff Albers, our Chief Executive Officer (CEO), has decided to step down and move into the position of Executive Chairman,…
Read moreBlueprint’s Biomarker Testing Program: KIT D816V Test Available for Eligible U.S. Patients Suspected of Having Systemic Mastocytosis
November 22, 2021
Receiving a timely diagnosis is difficult for many patients living with a rare disease. These challenges are particularly significant for systemic mastocytosis (SM), a rare…
Read moreFemale Leaders at Blueprint Medicines Bringing
Leadership across the Life Sciences Industry
October 22, 2021
At Blueprint Medicines, we believe diversity is a core strength of our business. By drawing upon a range of backgrounds, experiences and perspectives, we strengthen…
Read moreOur first decade of innovation in precision medicine
April 21, 2021
This month marks 10 years since Blueprint Medicines began operations, and it’s a natural time to celebrate the science, patients and people who have made…
Read moreJoining Other Precision Medicine Stakeholders to Develop United Language for Testing
June 11, 2020
With more biomarker-targeted therapies becoming available, patient advocacy groups have increasingly talked about the challenge of confusing terminology for cancer testing. In March 2019, my…
Read moreASCO 2019: Advancing Cancer Treatment with Precision Therapies
May 31, 2019
At the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, a key focus will be precision therapy – targeting genetic drivers of cancer with…
Read moreBlueprint Medicines Recognizes International FOP Awareness Day
April 23, 2019
Letter from Marion Dorsch, Chief Scientific Officer Today, Blueprint Medicines stands with the patient community and recognizes International Fibrodysplasia Ossificans Progressiva (FOP) Awareness Day. In…
Read moreHow Our Research Platform Helped Accelerate the Discovery of BLU-667
April 10, 2019
Discovering potent and selective kinase drugs is a challenging endeavor. Setting up and completing a screen of a new drug target against a compound library…
Read moreBlueprint Medicines Introduces The Lens
January 2, 2019
Welcome to The Lens, our new thought leadership platform to share our team’s expertise in precision medicine. We are pioneers in this rapidly evolving field,…
Read more